Editions:  Austria · Denmark · France · Germany · Italy · Norway · Spain · Sweden · Switzerland
Advertisement

Drugs giant Novartis posts stable earnings

Share this article

Drugs giant Novartis posts stable earnings
Photo: Andrew Hecht
10:35 CEST+02:00
Swiss pharmaceutical group Novartis said Thursday that its net profit remained stable in the third quarter and confirmed that it was on track to meet its 2012 sales target.

Novartis, which is in the spotlight after three European countries halted sales of two of its flu vaccines on Wednesday, announced net profit of $2.5 billion between July and September.

Operating profit rose 3 percent to $3 billion over the same period but sales fell 7 percent to $13.8 billion.

Novartis CEO Joseph Jimenez blamed the lower sales on patents expiring on the group's cancer treatment drug Diovan and "a down quarter in Sandoz and Consumer Health."

But new products "had performed well and represent 29 percent of group sales", said Jiminez, saying he remained "confident that this improves the long-term growth prospects of the business", with 2012 sales expected to remain stable compared with 2011.

In Europe, the Basel-based group reacted to a sales freeze on its flu vaccines in Italy, Switzerland and Austria after concerns about impurities, saying that there was "no impact on the safety or efficacy of the vaccine."

Get notified about breaking news on The Local

Share this article

Advertisement

From our sponsors

You won't believe how many Stockholmers are actually immigrants

To celebrate International Migrants Day, the team at Beyond Borders hit the streets to chat with Stockholmers about where they come from.

Advertisement
Advertisement
Jobs
Click here to start your job search
Advertisement
Advertisement

Popular articles

Advertisement
Advertisement